Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CPA1 | P15085 | 4/20 | 0.58 |
| ▸ | CPA3 | P15088 | 3/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8531397 | 0.91 | CYP1A2 (0.54) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL5418068 | 0.91 | CYP1A2 (0.55) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7437992 | 0.86 | ALDH1A1 (0.54) | CYP1A2CPA1 | |
| SCHEMBL27682962 | 0.86 | CYP1A2 (0.50) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL8500824 | 0.84 | CYP1A2 (0.53) | CYP1A2CPA1CPA3 | |
| SCHEMBL7273483 | 0.84 | CYP1A2 (0.63) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL8500821 | 0.84 | CYP1A2 (0.53) | CYP1A2CPA1CPA3 | |
| SCHEMBL7273492 | 0.84 | CYP1A2 (0.63) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL162841 | 0.81 | CYP1A2 (0.70) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7053102 | 0.81 | CPA3 (0.63) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1682702-A | Method for preparing pharmaceutical composition capable of inhibiting postinfectious viral protease | ALBERT LAB (US) | 2005-10-19 | — | — | CN | disclosed |
| CN-1253019-A | Method for preparing pharmaceutical composition capable of inhibiting postinfectious viral protease | ALBERT LAB (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |